U.S. health body questions robustness of AstraZeneca's COVID-19 vaccine trial data
AstraZeneca may have provided an incomplete view of efficacy data on its COVID-19 vaccine from a large scale trial in the United States, a U.S. health agency, in a fresh setback for the shot.